CSL Ltd CSL
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CSL is a good fit for your portfolio.
News
-
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
-
EU Secures More Than 40 Million Bird Flu Vaccines
-
CSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza
-
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
-
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
-
Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons
-
Mark Cuban Foundation and CSL Bring AI Bootcamp to Philadelphia Teens
-
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
Trading Information
- Previous Close Price
- A$297.50
- Day Range
- A$297.02–300.00
- 52-Week Range
- A$228.65–306.42
- Bid/Ask
- A$299.61 / A$300.00
- Market Cap
- A$144.86 Bil
- Volume/Avg
- 656,741 / 730,394
Key Statistics
- Price/Earnings (Normalized)
- 30.93
- Price/Sales
- 6.88
- Dividend Yield (Trailing)
- 1.27%
- Dividend Yield (Forward)
- 1.27%
- Total Yield
- 1.27%
Company Profile
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 30,000
- Website
- https://www.csl.com
Competitors
Valuation
|
Metric
|
CSL
|
4502
|
SNY
|
|---|---|---|---|
Price/Earnings (Normalized) | 30.93 | 16.10 | 10.72 |
Price/Book Value | 5.74 | 0.92 | 1.60 |
Price/Sales | 6.88 | 1.57 | 2.42 |
Price/Cash Flow | 35.89 | 7.69 | 11.95 |
Price/Earnings
CSL
4502
SNY
Financial Strength
|
Metric
|
CSL
|
4502
|
SNY
|
|---|---|---|---|
Quick Ratio | 0.95 | 0.51 | 0.83 |
Current Ratio | 2.15 | 1.11 | 1.27 |
Interest Coverage | 7.21 | 1.35 | 8.40 |
Quick Ratio
CSL
4502
SNY
Profitability
|
Metric
|
CSL
|
4502
|
SNY
|
|---|---|---|---|
Return on Assets (Normalized) | 8.11% | 5.19% | — |
Return on Equity (Normalized) | 18.17% | 11.01% | — |
Return on Invested Capital (Normalized) | 10.94% | 7.28% | — |
Return on Assets
CSL
4502
SNY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Lpnsfmfh | Vmjh | $628.7 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Rqmnztk | Mkvsdz | $121.4 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Bszqwdym | Bpjbg | $114.0 Bil | |||
| Moderna Inc
MRNA
| Yydnlfft | Gvvyk | $45.3 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zxtbybmn | Bvlrkl | $31.5 Bil | |||
| argenx SE ADR
ARGX
| Jsxvfcfj | Vtzd | $25.9 Bil | |||
| BioNTech SE ADR
BNTX
| Pmnrbnsb | Pwzq | $19.2 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Pzyhgpvl | Gzqkkc | $15.4 Bil | |||
| United Therapeutics Corp
UTHR
| Gkrcqcnhk | Vtf | $14.0 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Tvnryprjz | Jbnxsr | $11.7 Bil |